Kara Carter

Dr. Kara Carter is CEO of Viraccio Therapeutics, leveraging proximity induction with disease selective effectors to discover and develop therapeutics. Most recently she was EVP at Evotec leading a portfolio of programs as well as leading an incubated company in the antiviral space. Dr. Carter was the founding head of the Sanofi virology therapeutic area, developing a portfolio of biologics and small molecule programs and leading the transition of that group from Sanofi to Evotec. As an EVP at Evotec, she continued to expand the portfolio and advance programs to preclinical and clinical development. Prior to that, she held positions of increasing responsibility at Genzyme leading small molecule discovery programs in oncology, renal biology, neurobiology, immunology, and rare disease. She has also had roles at PRAECIS Pharmaceuticals and Dewpoint Therapeutics. Dr. Carter has extensive experience in drug discovery and early development leading teams in the US, France and China. In 2018, Dr. Carter was elected President of the International Society for Antiviral Research and currently serves as a Past President of the Society. She was an active member of both the COVID R&D consortium and the ACTIV public private partnership responding to the COVID-19 pandemic. Dr. Carter did her undergraduate studies at Stanford University, her doctoral work at the University of Chicago, and post-doctoral studies at Harvard University.